>
Bots Now Outnumber Humans Online And The Internet Was Never Built For This
Tulsi Gabbard Makes a Grand Exit
Pakistan Says US-Iran Deal 'Has Been Reached'
With One Strike, Netanyahu Tries To Kill Two Peace Deals
Heads up: Apparently the government is hiding cameras inside fake utility boxes
Sodium Batteries And EVs That Power The Grid: Inside GM's Big Energy Push
NUCLEAR ENGINE - UNLIMITED LUXURY - 20 YEARS WITHOUT REFUELING
China Unveils Nuclear-Powered Floating Hub For Green Shipping
China Launches World's 1st Commercial Brain Chip, Beating Elon Musk's Neuralink!
Modular next-gen US nuclear reactor goes critical
This Company Will Add Phone, AirPod, and Smartwatch Trackers to License Plate Readers
Elon Details SpaceX AI Data Center in Space Details and Roadmap

Over the past year, the gap between the super-rich and the rest of us has grown wider than ever before.
But the difference between ordinary people and billionaires might be more than just money. Some high net worth individuals have been looking into extending their lives far beyond the 70 or 80 years most of us might hope for.
Peter Thiel, for example, the billionaire co-founder of PayPal, has invested in a number medical research start-ups looking extending life expectancy though his Breakout Labs fund.
One of the companies longevity obsessive Thiel has bankrolled is Ambrosia.
Ambrosia is one of three outfits looking at experimental "vampire" blood transfusions that put the blood of young people into the lens of oldies.
According to commercial finance experts ABC Finance, the cost of the trials currently ranges from £6,000 to about £215,000.